Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NuVasive, Inc.    NUVA

NUVASIVE, INC.

(NUVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/02/2020 04/03/2020 04/06/2020 04/07/2020 04/08/2020 Date
44.98(c) 43.51(c) 46.39(c) 50.51(c) 53.63 Last
1 030 197 721 579 1 672 057 1 575 539 671 851 Volume
+0.27% -3.27% +6.62% +8.88% +6.18% Change
More quotes
Financials (USD)
Sales 2020 1 195 M
EBIT 2020 188 M
Net income 2020 69,9 M
Debt 2020 339 M
Yield 2020 -
Sales 2021 1 286 M
EBIT 2021 212 M
Net income 2021 94,0 M
Debt 2021 250 M
Yield 2021 -
P/E ratio 2020 38,0x
P/E ratio 2021 27,5x
EV / Sales2020 2,49x
EV / Sales2021 2,24x
Capitalization 2 634 M
More Financials
Company
Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal... 
More about the company
Surperformance© ratings of NuVasive, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on NUVASIVE, INC.
03/10NUVASIVE : Randomized Controlled Trial Results Published in 'Spine' Demonstrate ..
PR
03/02NUVASIVE INC : Entry into a Material Definitive Agreement, Creation of a Direct ..
AQ
03/02NUVASIVE : to Participate at Spine Summit 2020
PR
02/27NUVASIVE : to Participate in Cowen 40th Annual Healthcare Conference
PR
02/27NUVASIVE INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/27NUVASIVE, INC. : Announces Pricing Of Offering Of $450 Million Of 0.375% Convert..
PR
02/26NUVASIVE INC : Entry into a Material Definitive Agreement, Creation of a Direct ..
AQ
02/26NUVASIVE, INC. : Announces Proposed Offering Of $450 Million Of Convertible Seni..
PR
02/20NUVASIVE : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
02/20NUVASIVE : 4Q Earnings Snapshot
AQ
02/20NUVASIVE INC : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
02/20NUVASIVE : Announces Fourth Quarter and Full Year 2019 Financial Results
PR
02/13NUVASIVE : Results Validating the Versatility of NuVasive's MaXcess® Retractor i..
PR
02/04NUVASIVE : Announces Conference Call and Webcast of Fourth Quarter and Full Year..
PR
01/13NUVASIVE INC : Results of Operations and Financial Condition (form 8-K)
AQ
More news
News in other languages on NUVASIVE, INC.
2019L'Europe finit en nette hausse, espoir sur le commerce et les banques
2019STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe (actualisé)
2019PROTHÈSES : Smith&Nephew veut racheter l'américain NuVasive
2014NUVASIVE, INC. : publication des résultats trimestriels
2013NuVasive(R) baut sein Führungsteam in Europa weiter aus
More news
Chart NUVASIVE, INC.
Duration : Period :
NuVasive, Inc. Technical Analysis Chart | NUVA | US6707041058 | MarketScreener
Technical analysis trends NUVASIVE, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 75,53  $
Last Close Price 50,51  $
Spread / Highest target 84,1%
Spread / Average Target 49,5%
Spread / Lowest Target 2,95%
EPS Revisions
Managers
NameTitle
J. Christopher Barry Chief Executive Officer & Director
Matthew W. Link President
Dale Wolf Senior Vice President-Global Operations
Matthew K. Harbaugh Chief Financial Officer & Executive Vice President
Kyle Malone VP-Clinical, Medical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
NUVASIVE, INC.-34.69%2 634
MEDTRONIC PLC-16.74%126 592
BAXTER INTERNATIONAL INC.-1.33%41 850
HOYA CORPORATION-2.80%33 246
TERUMO CORPORATION-1.68%25 446
DEXCOM, INC.14.62%22 964